These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2190094)

  • 1. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.
    Roche PA; Cresswell P
    Nature; 1990 Jun; 345(6276):615-8. PubMed ID: 2190094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
    Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular transport and peptide binding properties of HLA class II glycoproteins.
    Cresswell P; Avva RR; Davis JE; Lamb CA; Riberdy JM; Roche PA
    Semin Immunol; 1990 Jul; 2(4):273-80. PubMed ID: 2104276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
    Pinet V; Malnati MS; Long EO
    J Immunol; 1994 May; 152(10):4852-60. PubMed ID: 8176208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HLA system, antigen processing and presentation.
    Krensky AM
    Kidney Int Suppl; 1997 Mar; 58():S2-7. PubMed ID: 9067934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.
    Roche PA; Marks MS; Cresswell P
    Nature; 1991 Dec; 354(6352):392-4. PubMed ID: 1956401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DR alpha beta dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones.
    Demotz S
    Eur J Immunol; 1993 Sep; 23(9):2100-8. PubMed ID: 8370392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
    Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
    J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
    Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
    Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen presentation mediated by recycling of surface HLA-DR molecules.
    Pinet V; Vergelli M; Martin R; Bakke O; Long EO
    Nature; 1995 Jun; 375(6532):603-6. PubMed ID: 7540726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
    Long EO; LaVaute T; Pinet V; Jaraquemada D
    J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells.
    Nygard NR; Giacoletto KS; Bono C; Gorka J; Kompelli S; Schwartz BD
    J Immunol; 1994 Feb; 152(3):1082-93. PubMed ID: 8301118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly and transport of MHC class II molecules.
    Teyton L; Peterson PA
    New Biol; 1992 May; 4(5):441-7. PubMed ID: 1515409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR.
    Roche PA; Cresswell P
    J Immunol; 1990 Mar; 144(5):1849-56. PubMed ID: 2307844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of binding capacities between HLA class II molecules and synthetic peptides HA307-319].
    Ikeda K; Katagiri M
    Hokkaido Igaku Zasshi; 1993 May; 68(3):318-24. PubMed ID: 8319931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
    Monji T; McCormack AL; Yates JR; Pious D
    J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.